Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$19.7 million.

  • Capricor Therapeutics' Cash from Operations fell 6911.17% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.0 million, marking a year-over-year decrease of 6590.13%. This contributed to the annual value of -$40.0 million for FY2024, which is 5625.45% down from last year.
  • Capricor Therapeutics' Cash from Operations amounted to -$19.7 million in Q3 2025, which was down 6911.17% from -$20.1 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Cash from Operations high stood at $24.0 million for Q1 2022, and its period low was -$20.1 million during Q2 2025.
  • For the 5-year period, Capricor Therapeutics' Cash from Operations averaged around -$6.5 million, with its median value being -$6.5 million (2022).
  • Per our database at Business Quant, Capricor Therapeutics' Cash from Operations soared by 82225.57% in 2022 and then tumbled by 40719.94% in 2025.
  • Capricor Therapeutics' Cash from Operations (Quarter) stood at -$5.6 million in 2021, then fell by 22.65% to -$6.9 million in 2022, then tumbled by 67.98% to -$11.6 million in 2023, then dropped by 27.62% to -$14.8 million in 2024, then crashed by 33.07% to -$19.7 million in 2025.
  • Its last three reported values are -$19.7 million in Q3 2025, -$20.1 million for Q2 2025, and -$6.4 million during Q1 2025.